The company focuses on developing human parthenogenetic stem cells for therapeutic applications. This initial launch will focus on the company’s existing Lifeline Skin Care customers.
According to the CDC, osteoarthritis is the most common form of degenerative joint disease and affects approximately 630 million people around the globe. Technavio analysts predict that the global bone and joint supplements market will reach $3.3 billion by the end of 2023.
More articles on biologics:
How Dr. Kevin Stone helped Super Bowl champion Tracy Porter make a comeback — 6 details
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
